TP012/#1530 Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib in subjects with platinum sensitive recurrent ovarian cancer: flora-4
Conferences
Duska, L; Richardson, D; Jada, SR; Gupta, S; Teja, TR; Secord, AA
Published in: International Journal of Gynecological Cancer
November 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
International Journal of Gynecological Cancer
DOI
ISSN
1048-891X
Publication Date
November 2023
Volume
33
Start / End Page
A251 / A251
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Duska, L., Richardson, D., Jada, S. R., Gupta, S., Teja, T. R., & Secord, A. A. (2023). TP012/#1530 Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib in subjects with platinum sensitive recurrent ovarian cancer: flora-4. In International Journal of Gynecological Cancer (Vol. 33, pp. A251–A251). Elsevier BV. https://doi.org/10.1136/ijgc-2023-igcs.474
Duska, Linda, Debra Richardson, Srinivasa Rao Jada, Sunil Gupta, Tl Raj Teja, and Angeles Alvarez Secord. “TP012/#1530 Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib in subjects with platinum sensitive recurrent ovarian cancer: flora-4.” In International Journal of Gynecological Cancer, 33:A251–A251. Elsevier BV, 2023. https://doi.org/10.1136/ijgc-2023-igcs.474.
Duska L, Richardson D, Jada SR, Gupta S, Teja TR, Secord AA. TP012/#1530 Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib in subjects with platinum sensitive recurrent ovarian cancer: flora-4. In: International Journal of Gynecological Cancer. Elsevier BV; 2023. p. A251–A251.
Duska, Linda, et al. “TP012/#1530 Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib in subjects with platinum sensitive recurrent ovarian cancer: flora-4.” International Journal of Gynecological Cancer, vol. 33, Elsevier BV, 2023, pp. A251–A251. Crossref, doi:10.1136/ijgc-2023-igcs.474.
Duska L, Richardson D, Jada SR, Gupta S, Teja TR, Secord AA. TP012/#1530 Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib in subjects with platinum sensitive recurrent ovarian cancer: flora-4. International Journal of Gynecological Cancer. Elsevier BV; 2023. p. A251–A251.
Published In
International Journal of Gynecological Cancer
DOI
ISSN
1048-891X
Publication Date
November 2023
Volume
33
Start / End Page
A251 / A251
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences